Nontuberculous mycobacterial (NTM) infections are caused by mycobacterial species other than Mycobacterium tuberculosis, and they frequently lead to chronic pulmonary and extrapulmonary infections. These infections are difficult to diagnose and treat due to their diverse clinical presentations and resistance to standard antibiotics. Pulmonary NTM infections are especially common in individuals with underlying lung diseases such as cystic fibrosis or chronic obstructive pulmonary disease (COPD). Current treatment options are limited, highlighting a significant need for more effective therapies.

Track the trends in DCM & more—explore the data visually!: Click Here

NTM Infections Epidemiological Segmentation

The epidemiological segmentation of NTM infections across the 7 major markets (7MM) from 2020 to 2034 includes:

• Total prevalent cases
  
• Total diagnosed prevalent cases
  
• Gender-specific cases
  
• Species-specific cases
  
• Type-specific cases
  
• Severity-specific cases
  

NTM Infections Epidemiology

In 2023, the prevalence of NTM infections in the 7MM exhibited notable trends:

• In the United States, there were approximately 108,000 diagnosed prevalent cases.
  
• Of these, 68% were female and 32% were male.
  
• Among the diagnosed population, 86,000 had pulmonary NTM infections, while 22,000 had extrapulmonary infections.

Break down the numbers. Understand the strategy. Download the report: Click Here

NTM Infections Market

The estimated market size for NTM infections in the United States was around USD 360 million in 2023.

NTM Infections Market Drivers

• The development of novel therapies such as Epetraborole, MNKD-101, and SPR720 is expected to significantly improve the treatment paradigm by offering targeted action against specific NTM species with enhanced efficacy and safety.
  
• Increasing awareness about NTM infections and progress in diagnostic technologies are facilitating earlier detection, improving disease management, and contributing to market growth.
  

NTM Infections Market Barriers

• The diversity of NTM species and their varied clinical manifestations complicate treatment selection and clinical trial design, making therapeutic responses less predictable.
  
• High treatment costs and limited access—particularly in underserved areas—remain key challenges to broader market adoption.
  

NTM Infections Emerging Therapies

• Epetraborole
  
• MNKD-101
  
• SPR720
  
• And others
  

NTM Infections Key Players

• Insmed Incorporated
  
• RedHill Biopharma
  
• Novoteris
  
• Savara Inc.
  
• Beyond Air
  
• And others
  

Download the full infographic to uncover detailed insights: Click Here